2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.
Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.
Gilbert explains that there are complications in the various components of precision medicine and by breaking them down, there may be a greater understanding in treating these patients. These components include tumor heterogeneity, he adds.
Research conducted within The Cancer Genome Atlas has shown that there is differentiation within various cells of one tumor. Therefore, making informed treatment decisions based on original diagnostic tissue should not be done, Gilbert says.
<<<
Related Content: